Compound · clinical trials

Adrucil clinical trials

Also listed in trial records as 5-Fluorouracil, 5-FU, Fluorouracil-GRY

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 163 trials in our China, USA, Japan, Spain, Italy, Germany, France, Canada, Taiwan, South Korea, UK, Mexico, Australia, Netherlands, Poland, Israel, Turkey, Brazil, Belgium, Norway, Czechia, Switzerland, Sweden, Egypt, Denmark, India, Singapore, Portugal, Austria and Ireland registers that name Adrucil as an intervention. Synced 13 Nov 2026

163Current trials

97Recruiting now

93Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany

Compiled from ClinicalTrials.gov registry records · Synced 13 Nov 2026 · Editorial standards

At a glance

Adrucil is named as an intervention in 163 current clinical trials in our China, USA, Japan, Spain, Italy, Germany, France, Canada, Taiwan, South Korea, UK, Mexico, Australia, Netherlands, Poland, Israel, Turkey, Brazil, Belgium, Norway, Czechia, Switzerland, Sweden, Egypt, Denmark, India, Singapore, Portugal, Austria and Ireland registers. 97 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Sun Yat-sen University (10). The most-studied condition is Colorectal Cancer.

Where Adrucil is approved

All regulators →

USUnited States (FDA)

No FDA approval of a single-substance product in Drugs@FDA

First original NDA/BLA approval

EUEuropean Union (EMA)

No centralised EU authorisation (it may be authorised nationally)

First centralised authorisation

CACanada (Health Canada)

No new-drug Notice of Compliance since 1994

First new-drug NOC

1 EU safety letter (DHPC), latest: periodic safety update single assessment for 5 fluorouracil, 24 Oct 2024

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

Patient leaflets for Adrucil

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting9760%
Not yet open1610%
Active, closed4829%
By invitation21%

Trials by phase

Phase 25936%
Phase 35333%
Phase 1/21811%
Phase 1149%
Phase 2/3106%
Not applicable53%
Phase 421%
Observational11%
Early Phase 111%

Clinical trials of Adrucil

163 trials

Study	Phase	Status	Lead sponsor	Registers
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials NCT05203172 · Solid Tumors	Phase 4	Recruiting	Pfizer	UK, USA, Germany, France, Spain, Italy, Netherlands, Czechia, Portugal, Turkey, Canada, Brazil, South Korea, Australia, Israel
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer NCT01954992 · Metastatic Pancreatic Adenocarcinoma	Phase 3	Recruiting	Eleison Pharmaceuticals LLC	USA
Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer NCT02535221 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	Peking University	China
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver NCT02885753 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 3	Recruiting	Federation Francophone de Cancerologie Digestive	France, Belgium
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC NCT03303495 · ClinicalTrials.gov ↗ · Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms	Phase 3	Recruiting	Sun Yat-sen University	China
Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer NCT04215731 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 3	Recruiting	Yanhong Deng	China
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) NCT04447352 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Krankenhaus Nordwest	Germany
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma NCT04997837 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Recruiting	Fudan University	China
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) NCT05008809 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Recruiting	Dominik Paul Modest	Germany
Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer NCT05201430 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 3	Recruiting	Fudan University	China
Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature NCT05314998 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma	Phase 3	Recruiting	John Neoptolemos	Germany, Sweden
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma NCT05677490 · ClinicalTrials.gov ↗ · Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Alliance for Clinical Trials in Oncology	Mexico
Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer NCT06509126 · ClinicalTrials.gov ↗ · Colorectal Cancer Stage IV	Phase 3	Recruiting	National Cancer Institute, Naples	Italy
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer NCT06662786 · Colorectal Neoplasms	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Israel
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases NCT06699212 · Recurrent Head and Neck Squamous Cell Carcinoma	Phase 3	Recruiting	Rakuten Medical, Inc	USA, China, Japan, Taiwan
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. NCT06733038 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Recruiting	Gruppo Oncologico del Nord-Ovest	Italy
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy NCT06750094 · Colorectal Neoplasms	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Turkey, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer NCT06764875 · HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma NCT06793917 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Recruiting	Fujian Cancer Hospital	China
Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer. NCT06897644 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma Advanced or Metastatic	Phase 3	Recruiting	Gruppo Oncologico del Nord-Ovest	Italy
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer NCT06901531 · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer	Phase 3	Recruiting	Astellas Pharma Global Development, Inc	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Portugal, Turkey, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer NCT06958328 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8	Phase 3	Recruiting	NRG Oncology	Canada
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) NCT06997497 · Colon Adenocarcinoma, Rectal Adenocarcinoma	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC NCT07026474 · ClinicalTrials.gov ↗ · Recurrent Head and Neck Squamous Cell Carcinoma	Phase 3	Recruiting	Universität des Saarlandes	Germany, Switzerland
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma NCT07043400 · Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	BeOne Medicines	UK, USA, China, France, Spain, Italy, Poland, Austria, Czechia, Turkey, Brazil, Mexico, Japan, South Korea
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study NCT07097142 · ClinicalTrials.gov ↗ · Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8	Phase 3	Recruiting	NRG Oncology	Canada
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer NCT07228832 · Metastatic Colorectal Cancer (CRC)	Phase 3	Recruiting	Summit Therapeutics	UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Czechia, Canada, Mexico, Japan, Egypt
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial NCT07271355 · ClinicalTrials.gov ↗ · Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum	Phase 3	Recruiting	City of Hope Medical Center	Egypt
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer NCT07409272 · Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma	Phase 3	Recruiting	Astellas Pharma Global Development, Inc	UK, USA, China, Germany, France, Spain, Poland, Brazil, Japan, South Korea, Taiwan
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer NCT07412613 · ClinicalTrials.gov ↗ · Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer	Phase 3	Recruiting	Akeso	China
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 NCT07431281 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer NCT07472868 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Carcinoma	Phase 3	Recruiting	J. W. A. Burger	Netherlands
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) NCT07621718 · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC	Phase 3	Recruiting	Revolution Medicines, Inc	UK, USA, Italy, Netherlands, Austria
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer NCT07673887 · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 3	Recruiting	Astellas Pharma Global Development, Inc	USA, China, Japan
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) NCT07775287 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Recruiting	Genmab	USA
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) NCT07829783 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Taiwan
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC NCT05125055 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1	Phase 2/3	Recruiting	Shanghai Jiao Tong University School of Medicine	China
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients NCT06280495 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastases	Phase 2/3	Recruiting	Sun Yat-sen University	China
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer NCT06441565 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2/3	Recruiting	Sun Yat-sen University	China
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) NCT07554456 · Esophageal Squamous Cell Carcinoma	Phase 2/3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction NCT04840264 · ClinicalTrials.gov ↗ · Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis	Phase 2	Recruiting	Sixth Affiliated Hospital, Sun Yat-sen University	China
ATATcH Alternating Treatment Plans for Advanced Cancer NCT05358548 · ClinicalTrials.gov ↗ · Head and Neck Cancer, Lung Cancer	Phase 2	Recruiting	Rutgers, The State University of New Jersey	Israel
A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) NCT05472259 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Ductal Adenocarcinoma	Phase 2	Recruiting	Belgian Group of Digestive Oncology	Belgium
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) NCT05489211 · Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Poland, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial NCT05564377 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Mexico, Israel, Egypt
Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer NCT05571644 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma NCT05702229 · Gastric Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Spain, Japan, South Korea, Taiwan
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial NCT05862168 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma	Phase 2	Recruiting	Weijia Fang, MD	China
Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma NCT05960955 · ClinicalTrials.gov ↗ · Resectable Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	Akeso	China
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma NCT06019130 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharyngeal Neoplasms	Phase 2	Recruiting	German Society for Pediatric Oncology and Hematology GPOH gGmbH	Germany
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer NCT06184698 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	Hebei Medical University Fourth Hospital	China
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 NCT06219941 · Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Spain, Poland, Canada, Japan, South Korea, Taiwan, Singapore, Australia
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer NCT06341296 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	West China Hospital	China
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients NCT06493760 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd	China
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors NCT06535607 · Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Germany, Italy, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab NCT06540326 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma NCT06632717 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	National Taiwan University Hospital	Taiwan
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) NCT06730373 · ClinicalTrials.gov ↗ · HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma	Phase 2	Recruiting	Qilu Hospital of Shandong University	China
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial NCT06770582 · ClinicalTrials.gov ↗ · Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer NCT06928584 · ClinicalTrials.gov ↗ · Locally Recurrent Rectal Cancer	Phase 2	Recruiting	Fudan University	China
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer NCT06948448 · Colorectal Cancer	Phase 2	Recruiting	Ono Pharmaceutical Co., Ltd	USA, France, Spain, Italy, Canada, Japan
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma NCT07018570 · ClinicalTrials.gov ↗ · Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 2	Recruiting	National Cancer Center Hospital East	Japan
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma NCT07069712 · Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Spain, Italy, Poland, Turkey, Canada, Japan, Taiwan
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer NCT07150247 · ClinicalTrials.gov ↗ · BRAF V600 Colorectal Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression NCT07176182 · ClinicalTrials.gov ↗ · Rectal Cancer Patients, Rectal Cancer Stage II, Rectal Cancer Stage III	Phase 2	Recruiting	Sixth Affiliated Hospital, Sun Yat-sen University	China
Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R) NCT07183865 · ClinicalTrials.gov ↗ · Locally Recurrent Rectal Cancer	Phase 2	Recruiting	Fudan University	China
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] NCT07331155 · ClinicalTrials.gov ↗ · Advanced Solid Tumour	Phase 2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) NCT07432295 · Solid Tumor, Advanced Cancer, Metastatic Cancer	Phase 2	Recruiting	I-Mab Biopharma US Limited	USA, China, Japan, Egypt
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer NCT07474727 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	Multitude Therapeutics Inc	China
A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma NCT07484724 · ClinicalTrials.gov ↗ · Advanced Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Shanghai Junshi Bioscience Co., Ltd	China
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States NCT07554521 · Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	BeOne Medicines	USA
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma NCT07700667 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	China
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC NCT07733180 · ClinicalTrials.gov ↗ · Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	BeOne Medicines	Japan
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) NCT07793942 · ClinicalTrials.gov ↗ · Malignant Neoplam, Advanced Solid Tumors	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, Switzerland, Canada
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab NCT05319639 · ClinicalTrials.gov ↗ · Gastric Cancer Stage IV	Phase 1/2	Recruiting	Fujian Cancer Hospital	China
FOG-001 in Locally Advanced or Metastatic Solid Tumors NCT05919264 · ClinicalTrials.gov ↗ · Cancer, Colorectal Cancer, Solid Tumor	Phase 1/2	Recruiting	Parabilis Medicines, Inc	USA, Australia
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) NCT06428409 · Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Spain, Italy, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan, Australia
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) NCT06469944 · ClinicalTrials.gov ↗ · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China, Germany, France, Italy, Switzerland, Norway, Brazil, South Korea, Taiwan
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors NCT06741644 · Advanced Solid Tumors	Phase 1/2	Recruiting	CStone Pharmaceuticals	USA, China, Australia
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111 · Esophageal Squamous Cell Carcinoma	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China, Germany, France, Italy, Switzerland, Czechia, Norway, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore
Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV NCT06782685 · ClinicalTrials.gov ↗ · Advanced Pancreatic Cancer (Part 1)	Phase 1/2	Recruiting	Dai, Guanghai	China
AK129 Combination Therapy for Advanced Solid Tumors NCT06943820 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma	Phase 1/2	Recruiting	Akeso	China
Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer NCT07056777 · ClinicalTrials.gov ↗ · Gastrointestinal Cancer	Phase 1/2	Recruiting	Zhejiang Doer Biologics Co., Ltd	China
A Study of YL242 in Subjects With Advanced Solid Tumors NCT07197827 · Advanced Solid Tumor	Phase 1/2	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd	USA, China, Australia
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors NCT07256782 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	Qilu Pharmaceutical Co., Ltd	China
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors NCT07730021 · Locally Advanced or Metastatic Solid Tumors	Phase 1/2	Recruiting	Astellas Pharma Global Development, Inc	USA, Japan
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) NCT05067283 · Advanced Solid Tumors	Phase 1	Recruiting	Merck Sharp & Dohme LLC	USA, China, Spain, Italy, Denmark, Poland, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan, Australia, Israel
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors NCT06131840 · Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms	Phase 1	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	UK, USA, China, France, Spain, Netherlands, Sweden, Canada, Japan, Israel
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors NCT06657144 · Metastatic Solid Tumor, Advanced Solid Tumor	Phase 1	Recruiting	Coherus Oncology, Inc	USA, China, Taiwan
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer NCT06825624 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC)	Phase 1	Recruiting	Hansoh BioMedical R&D Company	China
The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer NCT06856447 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 1	Recruiting	toqa saad mohammed mohammed	Egypt
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer NCT07024615 · Pancreatic Ductal Adenocarcinoma	Phase 1	Recruiting	Astellas Pharma Global Development, Inc	USA
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805 · Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer	Phase 1	Recruiting	Pfizer	USA, France, Spain
Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer NCT05424692 · ClinicalTrials.gov ↗ · Colon Cancer, Rectal Cancer, Chemotherapy Effect	Not applicable	Recruiting	Peking Union Medical College Hospital	China
Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer. NCT06894797 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Not applicable	Recruiting	Peking University Cancer Hospital & Institute	China
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays NCT07283939 · ClinicalTrials.gov ↗ · Ampulla of Vater Carcinoma, Appendix Carcinoma, Carcinoma of Unknown Primary With Gastrointestinal Profile	Not applicable	Recruiting	Alliance for Clinical Trials in Oncology	Mexico
Efficacy of Topical Tyrosine Versus Topical 5-Fluorouracil With Fractional Erbium YAG Laser NCT07742982 · ClinicalTrials.gov ↗ · Focal Vitiligo	Early Phase 1	Recruiting	Aswan University	Egypt
A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma NCT07014540 · ClinicalTrials.gov ↗ · Neuroendocrine Carcinomas (NEC)	Phase 4	Not yet open	Beijing GoBroad Hospital	China
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC NCT05780294 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Leucogen, Chemotherapy	Phase 3	Not yet open	Sun Yat-sen University	China
Pre-Operative Treatment in REseCTable COlon CanceR NCT06899477 · ClinicalTrials.gov ↗ · Colo-rectal Cancer, Colon Cancer, Colon Carcinoma	Phase 3	Not yet open	Dominik Paul Modest	Germany
A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy NCT07803783 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)	Phase 3	Not yet open	MediLink Therapeutics (Suzhou) Co., Ltd	China
Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer NCT07916844 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer	Phase 3	Not yet open	Zhai Wenlong	China
An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC NCT04890522 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Metastasis, Chemotherapy	Phase 2/3	Not yet open	Sun Yat-sen University	China
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC NCT06648525 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Phase 2	Not yet open	Harbin Medical University	China
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC NCT06684158 · ClinicalTrials.gov ↗ · GC/GEJC	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer NCT06713057 · ClinicalTrials.gov ↗ · Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer	Phase 2	Not yet open	West China Hospital	China
PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment NCT07028424 · ClinicalTrials.gov ↗ · PDAC - Pancreatic Ductal Adenocarcinoma	Phase 2	Not yet open	GERCOR - Multidisciplinary Oncology Cooperative Group	France
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) NCT07621497 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC)	Phase 2	Not yet open	Sun Yat-sen University	China
A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation NCT07814417 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 2	Not yet open	Eli Lilly and Company	USA, China, Spain
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment NCT06370754 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 1/2	Not yet open	Fudan University	China
FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation NCT06409637 · ClinicalTrials.gov ↗ · Liver Cancer, Liver Transplant	Phase 1/2	Not yet open	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer NCT07314385 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma Metastatic, Liver Metastasis	Phase 1	Not yet open	National Taiwan University Hospital	Taiwan
Fractional CO2 Laser vs Dermabrasion With 5-Fluorouracil for Acquired Leukoderma NCT07837908 · ClinicalTrials.gov ↗ · Leukoderma, Hypopigmentation	Not applicable	Not yet open	Al-Azhar University	Egypt
Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer NCT07441369 · ClinicalTrials.gov ↗ · Liver Metastases From Colorectal Cancer (mCRC)	Phase 2	By invitation	Fudan University	China
Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study NCT04260269 · Solid Tumor	Observational	By invitation	Helsinki University Central Hospital	Ireland, Netherlands, Sweden, Denmark, Norway
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT00588770 · ClinicalTrials.gov ↗ · Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL) NCT02572141 · ClinicalTrials.gov ↗ · Colon Cancer	Phase 3	Active, closed	Sun Yat-sen University	China
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair NCT02912559 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome	Phase 3	Active, closed	National Cancer Institute (NCI)	Germany, Mexico, Israel
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study NCT02997228 · Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico
Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT NCT03340896 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 3	Active, closed	Groupe Oncologie Radiotherapie Tete et Cou	France
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery NCT03533582 · ClinicalTrials.gov ↗ · Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma	Phase 3	Active, closed	Children's Oncology Group	Canada, Mexico, Australia, Israel
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer NCT03775265 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Norway
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) NCT04241185 · Urinary Bladder Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, France, Spain, Italy, Netherlands, Denmark, Poland, Czechia, Portugal, Turkey, Japan, South Korea, Taiwan, Australia, Israel
Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients NCT04246684 · ClinicalTrials.gov ↗ · Rectal Cancer Stage III	Phase 3	Active, closed	Prof. Dr. med. Claus Rödel	Germany
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer NCT04607421 · Neoplasms	Phase 3	Active, closed	Pfizer	UK, USA, India, China, Germany, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Czechia, Norway, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB NCT04776655 · ClinicalTrials.gov ↗ · Colorectal Cancer, Metastatic Colorectal Cancer, RAS Mutation	Phase 3	Active, closed	Azienda USL Reggio Emilia - IRCCS	Italy
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers NCT05152147 · Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma	Phase 3	Active, closed	Jazz Pharmaceuticals	Ireland, UK, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) NCT05239741 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	China
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) NCT06625320 · Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma	Phase 3	Active, closed	Revolution Medicines, Inc	USA, Germany, France, Spain, Italy, Japan
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma NCT01924819 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2/3	Active, closed	Australasian Gastro-Intestinal Trials Group	Germany, France, Spain, Belgium, Czechia, Canada, Australia, Israel
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA NCT02135042 · ClinicalTrials.gov ↗ · EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7	Phase 2/3	Active, closed	NRG Oncology	China, Canada, Taiwan, Singapore, Australia
Nordic Pancreatic Cancer Trial (NorPACT) - 1 NCT02919787 · Pancreatic Cancer	Phase 2/3	Active, closed	Oslo University Hospital	Sweden, Denmark, Norway
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery NCT04068103 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8	Phase 2/3	Active, closed	NRG Oncology	Canada, Mexico
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response NCT05610163 · Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma	Phase 2/3	Active, closed	Alliance for Clinical Trials in Oncology	Mexico, Israel
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer NCT02299999 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 2	Active, closed	UNICANCER	France
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness NCT03421288 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 2	Active, closed	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Germany, Switzerland
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM NCT03493048 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastases	Phase 2	Active, closed	Sun Yat-sen University	China
Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer NCT03764553 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Active, closed	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Netherlands
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study NCT04166318 · Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico, Israel
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial NCT04216290 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. NCT04229459 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Active, closed	Baruch Brenner	Israel
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread NCT04233866 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) NCT04379596 · Gastric Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, China, Germany, Spain, Italy, Netherlands, Poland, Canada, Brazil, Japan, South Korea, Taiwan
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer NCT04390399 · Pancreatic Cancer	Phase 2	Active, closed	ImmunityBio, Inc	USA
Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29 NCT05253846 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Active, closed	Gruppo Oncologico del Nord-Ovest	Italy
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer NCT05382442 · Metastatic Colorectal Cancer	Phase 2	Active, closed	Akeso	USA, China
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin NCT05504252 · ClinicalTrials.gov ↗ · Colorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell Adenocarcinoma	Phase 2	Active, closed	University Hospital, Akershus	Norway
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) NCT05564403 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer NCT05843188 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Active, closed	University Health Network, Toronto	Canada
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors NCT05945823 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer	Phase 2	Active, closed	Taiho Oncology, Inc	USA, Germany, France, Spain
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer NCT06094140 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Active, closed	Australasian Gastro-Intestinal Trials Group	Australia
Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas NCT06557889 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck	Phase 2	Active, closed	Institut Claudius Regaud	France
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors NCT04083599 · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)	Phase 1/2	Active, closed	Genmab	UK, USA, China, Germany, France, Spain, Italy, Denmark, South Korea, Taiwan, Israel
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer NCT04821284 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8	Phase 1/2	Active, closed	Flemming Forsberg	Norway
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors NCT05229497 · ClinicalTrials.gov ↗ · Advanced Malignant Tumors	Phase 1/2	Active, closed	Akeso	China
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors NCT06771622 · ClinicalTrials.gov ↗ · Solid Cancer	Phase 1/2	Active, closed	FBD Biologics Limited	China
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) NCT05464030 · Colorectal Cancer	Phase 1	Active, closed	EMD Serono Research & Development Institute, Inc	USA, Spain, Canada, Japan, South Korea
First in Human Study of AZD9592 in Solid Tumors NCT05647122 · Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms	Phase 1	Active, closed	AstraZeneca	USA, China, France, Spain, Italy, Canada, Japan, South Korea, Taiwan, Australia
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors NCT06057038 · ClinicalTrials.gov ↗ · Malignant Solid Tumor	Phase 1	Active, closed	Genmab	Japan
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer NCT06328738 · HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors	Phase 1	Active, closed	Enliven Therapeutics	USA, France, Spain, Italy, Netherlands, Belgium, South Korea
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer NCT06547385 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 1	Active, closed	Ono Pharmaceutical Co., Ltd	Japan
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors NCT06586515 · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer	Phase 1	Active, closed	Eli Lilly and Company	Ireland, USA, China, Germany, France, Spain, Italy, Canada, Japan
Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma NCT03306901 · ClinicalTrials.gov ↗ · Esophageal Cancer	Not applicable	Active, closed	Samsung Medical Center	South Korea

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Adrucil

210 conditions

Colorectal Cancer18 Gastric Cancer11 Colorectal Neoplasms8 Pancreatic Cancer7 Pancreatic Ductal Adenocarcinoma6 Gastroesophageal Junction Adenocarcinoma5 Esophageal Squamous Cell Carcinoma5 Metastatic Colorectal Cancer5 Esophageal Cancer4 Advanced Solid Tumors4 Solid Tumor3Gastroesophageal Adenocarcinoma3

All 210 conditions

Condition (as registered)	Trials
Colorectal Cancer	18
Gastric Cancer	11
Colorectal Neoplasms	8
Pancreatic Cancer	7
Pancreatic Ductal Adenocarcinoma	6
Gastroesophageal Junction Adenocarcinoma	5
Esophageal Squamous Cell Carcinoma	5
Metastatic Colorectal Cancer	5
Esophageal Cancer	4
Advanced Solid Tumors	4
Solid Tumor	3
Gastroesophageal Adenocarcinoma	3
PDAC - Pancreatic Ductal Adenocarcinoma	3
Biliary Tract Cancer	3
HER2-positive Gastric Cancer	3
Metastatic Colorectal Cancer (CRC)	3
Colon Adenocarcinoma	3
Advanced Solid Tumor	3
Chemotherapy	3
Colon Cancer	3
Nasopharyngeal Carcinoma	3
Rectal Cancer	3
Metastatic Pancreatic Adenocarcinoma	3
Esophageal Adenocarcinoma	2
PDAC	2
Metastatic Gastric Adenocarcinoma	2
Metastatic Colorectal Adenocarcinoma	2
Recurrent Head and Neck Squamous Cell Carcinoma	2
Oral Squamous Cell Carcinoma	2
Rectal Cancer Stage III	2
Colorectal Adenocarcinoma	2
Liver Metastases	2
Metastatic Pancreatic Cancer	2
Locally Recurrent Rectal Cancer	2
Locally Advanced Rectal Cancer	2
Bladder Urothelial Carcinoma	2
Stage II Bladder Cancer AJCC v8	2
Stage IIIA Bladder Cancer AJCC v8	2
Metastatic Pancreatic Ductal Adenocarcinoma	2
Stage II Pancreatic Cancer AJCC v8	2
Stage IV Pancreatic Cancer AJCC v8	2
Advanced Esophageal Squamous Cell Carcinoma	2
Malignant Solid Tumor	2
Gastroesophageal Junction (GEJ) Adenocarcinoma	2
Colon Carcinoma	2
Non-small Cell Lung Cancer	1
Gastric Neoplasms	1
Carcinoma, Non-Small-Cell Lung	1
Stomach Neoplasms	1
Pancreatic Cancer Metastatic	1
Gastroesophageal Junction Cancer	1
Solid Tumors	1
Endometrial Cancer	1
Metastatic Castration-resistant Prostate Cancer	1
Ovarian Cancer	1
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer	1
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer	1
Metastatic Gastric Adenocarcinoma or Cancer	1
Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma	1
Rectal Adenocarcinoma	1
Cancer	1
Locally Advanced Solid Tumor	1
Advanced Unresectable Gastric Adenocarcinoma	1
Advanced Gastroesophageal Adenocarcinoma	1
Malignant Neoplam	1
Advanced Solid Tumours	1
Carcinoma Non-small Cell Lung	1
Head and Neck Neoplasms	1
Gastroesophageal Junction	1
Esophageal Neoplasms	1
Locally Advanced or Metastatic Solid Tumors	1
Advanced Breast Cancer	1
Metastatic Breast Cancer (HR+/ HER2-)	1
HER2-positive Breast Cancer	1
HER2 Positive Solid Tumors	1
HER2 Amplification	1
Metastatic Solid Tumor	1
Intrahepatic Cholangiocarcinoma (Icc)	1
Neoadjvant Therapy	1
Anti-PD-1	1
Rectal Cancer Patients	1
Rectal Cancer Stage II	1
Metastasis	1
Immunotherapy	1
Non-small Cell Lung Cancer Stage IIIB/IV	1
Head and Neck Squamous Cell Carcinoma (HNSCC)	1
BRAF V600 Colorectal Cancer	1
Chemotherapy Effect	1
PTC	1
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma	1
Pancreatic Ductal Adenocarcinoma (PDAC)	1
Liver Cancer	1
Liver Transplant	1
Advanced Malignant Tumors	1
Liver Metastases From Colorectal Cancer (mCRC)	1
Advanced Solid Tumour	1
Cholangiocarcinoma	1
Gallbladder Cancer	1
GC/GEJC	1
Colorectal Cancer Metastatic	1
Gastric Cancer Stage IV	1
EBV Infection	1
Stage II Nasopharyngeal Carcinoma AJCC v7	1
Stage III Nasopharyngeal Carcinoma AJCC v7	1
Stage IVA Nasopharyngeal Carcinoma AJCC v7	1
Locally Advanced Thyroid Gland Carcinoma	1
Thyroid Cancer	1
Resectable Colon Cancer	1
MSI-H/dMMR Colorectal Cancer	1
Nasopharyngeal Cancer	1
Nasopharyngeal Neoplasms	1
Nasopharynx Cancer	1
DNA Repair Disorder	1
Lynch Syndrome	1
Stage III Colon Cancer AJCC v8	1
RAS Mutation	1
Colorectal Cancer Stage IV	1
Pancreatic Adenocarcinoma Advanced or Metastatic	1
Locally Advanced Rectal Carcinoma	1
Muscle Invasive Bladder Carcinoma	1
Mucinous Adenocarcinoma	1
Signet Ring Cell Adenocarcinoma	1
Locally Advanced Pancreatic Ductal Adenocarcinoma	1
Stage IIA Pancreatic Cancer AJCC v8	1
Stage IIA Colon Cancer AJCC v8	1
Childhood Hepatocellular Carcinoma	1
Childhood Malignant Liver Neoplasm	1
Fibrolamellar Carcinoma	1
Hepatoblastoma	1
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma	1
Stage III Pancreatic Cancer AJCC v8	1
Non-Muscle Invasive Bladder Urothelial Carcinoma	1
Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma	1
Stage I Bladder Cancer AJCC v8	1
Muscle Invasive Bladder Urothelial Carcinoma	1
Stage IV Colorectal Cancer AJCC v7	1
Advanced Biliary Tract Carcinoma	1
Advanced Gallbladder Carcinoma	1
Advanced Intrahepatic Cholangiocarcinoma	1
Recurrent Biliary Tract Carcinoma	1
Neck Squamous Cell Carcinoma of Unknown Primary	1
Recurrent Hypopharyngeal Squamous Cell Carcinoma	1
Recurrent Laryngeal Squamous Cell Carcinoma	1
Recurrent Laryngeal Verrucous Carcinoma	1
Advanced Malignant Solid Neoplasm	1
Anatomic Stage III Breast Cancer AJCC v8	1
Anatomic Stage IV Breast Cancer AJCC v8	1
Locally Advanced Malignant Solid Neoplasm	1
Advanced Esophageal Adenocarcinoma	1
Advanced Gastric Adenocarcinoma	1
Advanced Gastroesophageal Junction Adenocarcinoma	1
Clinical Stage III Esophageal Adenocarcinoma AJCC v8	1
Anal Basaloid Carcinoma	1
Anal Canal Cloacogenic Carcinoma	1
Anal Canal Squamous Cell Carcinoma	1
Anal Margin Squamous Cell Carcinoma	1
Stage II Rectal Cancer AJCC v8	1
Stage III Rectal Cancer AJCC v8	1
Locally Advanced Rectal Adenocarcinoma	1
Stage III Bladder Cancer AJCC v8	1
Metastatic Esophageal Squamous Cell Carcinoma	1
Hepatocellular Carcinoma	1
Focal Vitiligo	1
Metastatic Appendix Carcinoma	1
Metastatic Colorectal Carcinoma	1
Metastatic Malignant Neoplasm in the Peritoneum	1
Stage IV Appendix Carcinoma AJCC v8	1
Leukoderma	1
Hypopigmentation	1
Non-Small Cell Lung Cancer (NSCLC)	1
Colorectal Cancer (CRC)	1
Melanoma	1
Neoplasms	1
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)	1
Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)	1
Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)	1
Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)	1
Urinary Bladder Neoplasms	1
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer	1
Esophageal Squamous Cell Cancer	1
Siewert Type 1 GEJ Cancer	1
Gastric Adenocarcinoma	1
Advanced Cancer	1
Metastatic Cancer	1
Metastatic Gastric Cancer	1
Unresectable Gastric Carcinoma	1
Gastrointestinal Cancer	1
Neoplasm Metastasis	1
Intestinal Neoplasms	1
Gastrointestinal Neoplasms	1
Metastatic Gastroesophageal Junction Adenocarcinoma	1
Peritoneal Carcinomatosis	1
Advanced Pancreatic Cancer (Part 1)	1
Solid Cancer	1
Breast Cancer	1
Leucogen	1
Myelosuppression	1
Neuroendocrine Carcinomas (NEC)	1
Colo-rectal Cancer	1
Head and Neck Squamous Cell Carcinoma	1
Squamous Cell Carcinoma of Head and Neck	1
Metastatic Breast Cancer	1
Ampulla of Vater Carcinoma	1
Appendix Carcinoma	1
Carcinoma of Unknown Primary With Gastrointestinal Profile	1
Pancreatic Adenocarcinoma Metastatic	1
Liver Metastasis	1
Bladder Cancer	1
Head and Neck Cancer	1
Lung Cancer	1

By country register

Register	Trials	Recruiting
Clinical trials in China	87	61
Clinical trials in USA	49	36
Clinical trials in Japan	35	25
Clinical trials in Spain	32	19
Clinical trials in Italy	32	21
Clinical trials in Germany	30	18
Clinical trials in France	30	17
Clinical trials in Canada	29	18
Clinical trials in Taiwan	28	20
Clinical trials in South Korea	26	17
Clinical trials in UK	23	18
Clinical trials in Mexico	21	9
Clinical trials in Australia	21	13
Clinical trials in Netherlands	17	10
Clinical trials in Poland	17	13
Clinical trials in Israel	17	8
Clinical trials in Turkey	15	13
Clinical trials in Brazil	15	12
Clinical trials in Belgium	12	8
Clinical trials in Norway	8	2
Clinical trials in Czechia	8	5
Clinical trials in Switzerland	8	7
Clinical trials in Sweden	7	4
Clinical trials in Egypt	7	6
Clinical trials in Denmark	6	1
Clinical trials in India	6	4
Clinical trials in Singapore	5	3
Clinical trials in Portugal	4	2
Clinical trials in Austria	4	4
Clinical trials in Ireland	3	0

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Adrucil trials

How many clinical trials are testing Adrucil?

163 current trials in our China, USA, Japan, Spain, Italy, Germany, France, Canada, Taiwan, South Korea, UK, Mexico, Australia, Netherlands, Poland, Israel, Turkey, Brazil, Belgium, Norway, Czechia, Switzerland, Sweden, Egypt, Denmark, India, Singapore, Portugal, Austria and Ireland registers name Adrucil (also registered as 5-Fluorouracil) as a drug or biological intervention, as of the registry sync on 13 November 2026. Completed and withdrawn studies are not counted.

Are Adrucil trials recruiting patients?

Yes. 97 of the 163 trials are recruiting: 61 with sites in China, 36 with sites in USA, 25 with sites in Japan, 19 with sites in Spain, 21 with sites in Italy, 18 with sites in Germany, 17 with sites in France, 18 with sites in Canada, 20 with sites in Taiwan, 17 with sites in South Korea, 18 with sites in UK, 9 with sites in Mexico, 13 with sites in Australia, 10 with sites in Netherlands, 13 with sites in Poland, 8 with sites in Israel, 13 with sites in Turkey, 12 with sites in Brazil, 8 with sites in Belgium, 2 with sites in Norway, 5 with sites in Czechia, 7 with sites in Switzerland, 4 with sites in Sweden, 6 with sites in Egypt, 1 with sites in Denmark, 4 with sites in India, 3 with sites in Singapore, 2 with sites in Portugal and 4 with sites in Austria. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Adrucil clinical trials?

Sun Yat-sen University (10), AstraZeneca (9), Merck Sharp & Dohme LLC (9) and National Cancer Institute (NCI) (8), among 93 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Adrucil clinical trials in Ireland?

Yes. 3 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Adrucil works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Adrucil works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Adrucil (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 13 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.